Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Assets (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Current Assets for 13 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 20.61% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 20.61% increase, with the full-year FY2025 number at $1.2 billion, up 20.61% from a year prior.
  • Current Assets was $1.2 billion for Q4 2025 at Madrigal Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.3 billion in Q3 2025 to a low of $157.1 million in Q3 2022.
  • A 5-year average of $625.7 million and a median of $346.3 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 48.14% in 2022, then soared 351.72% in 2024.
  • Madrigal Pharmaceuticals' Current Assets stood at $271.7 million in 2021, then skyrocketed by 33.01% to $361.4 million in 2022, then soared by 76.35% to $637.3 million in 2023, then surged by 62.08% to $1.0 billion in 2024, then increased by 20.61% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Current Assets are $1.2 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.0 billion (Q2 2025).